At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 107 enrolled
Drug / intervention
Navarixin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Navarixin and Pembrolizumab for Solid Tumors and 3 related conditions. Completed, enrolled 107 participants across 14 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
CountriesAustralia, Canada, Israel, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartApr 2018
Primary CompletionMay 2021
TodayJul 2026
First PostedMar 22, 2018
Enrollment StartApr 10, 2018
Primary CompletionMay 19, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 8.3 years ago
Interventions
Navarixindrug
Oral capsules
Pembrolizumabbiological
Intravenous infusion